Amir Avraham is a finance executive with over 20 years of leadership experience in the high-tech and biotech sectors, focusing on financial strategy and mergers and acquisitions.

As CFO and General Manager of OCON Therapeutics, he directed strategic planning and raised over $15 million while managing global activities. Previously, he was CFO at Secure Islands Technologies, where he oversaw operations in the US, UK, and Switzerland, managed investor relations, and facilitated a $20 million fundraising round and the company’s acquisition by Microsoft. He has also held leadership roles at Van Leer Ventures and Deloitte. Mr. Avraham is a licensed CPA and holds an MBA in Finance from the Hebrew University of Jerusalem.

Inna brings over 20 years of experience in venture financing, portfolio management and M&As.

Prior to joining Revium, Inna co-founded SPAS™, an innovative cardiovascular solution which is now being adopted by several leading clinics in the US. Inna served as a managing partner at a $760 million sovereign fund focused on healthcare innovation where she managed a portfolio of medical devices and pharmaceutical companies with a combined exit value of over $1.5 billion. Inna has served on the boards of multiple US and Israeli startup companies.

Yoram Drucker is a serial entrepreneur with over 25 years of experience in business development, fundraising, and executive roles in the biotechnology sector.

He co-founded and contributed to the development of three publicly-traded biotech companies, including Brainstorm (NASDAQ:BCLI), where he served as COO and CEO, and Pluri Biotech (NASDAQ: PLUR; TLV:PLUR).

Arie brings to Revium 14 years of experience in accounting, audit and financial management of hi-tech and biotechnology companies.

Since 2018, he serves as Head of IPO & M&A Department at a one of the leading accounting firms of Israel. Prior to that, Mr. Gordashnikov served as an Audit Manager at Ernst & Young Israel. Mr. Arie is licensed CPA since 2012 and has extensive experience in RCC and PCAOB reporting.

Ohad is a seasoned pharmaceutical executive with over two decades of experience in drug development, CMC, and regulatory affairs.

He has led formulation and regulatory strategy efforts across a range of therapeutic areas and development stages. Prior to joining ReviumRx, Ohad held senior leadership roles at Insightec (TASE: EMTC), Rafa Laboratories, Tiltan Pharma, and BioLineRx (Nasdaq: BLRX), where he led the development of both innovative and generic drug products, including sterile injectables, semi-solids, and oral formulations.

Ohad holds a Ph.D. in Pharmaceutics, an MBA, and a B.Pharm from the Hebrew University of Jerusalem.

Erez joined Revium in 2023, bringing over 15 years of experience in pharma and biotech R&D.

He previously served as Head of Early-Stage CMC at Clexio Biosciences, where he was responsible for formulation development and phase 1-2 regulatory submissions. Prior to that, Erez led the Innovative R&D Pharma Lab at Teva Pharmaceuticals. He also led CMC activities at Lipocure Ltd. and contributed to the FDA submission and approval of a liposomal drug product (ANDA). Erez holds a Ph.D. in pharmaceutical sciences and completed postdoctoral training at Northeastern University (Boston, MA). Erez has authored over 40 peer-reviewed papers and contributed to five patent applications.